



# The complexity of Health Technology Assessment and Evaluation for Medical Devices

Lord Darzi said:


“ We will foster a pioneering NHS. ... Continuous advances in clinical practice mean the NHS constantly has the opportunity to improve. My review will enable this through: ...

Ensuring that clinically and cost effective innovation in medicines and medical technologies is adopted. ... For new medical technologies, we will **simplify the pathway** by which they pass from development into wider use, and develop ways to benchmark and monitor uptake.”

*The NHS Next Stage Review Final Report:*

## System and Participants

There are many participants with diverse goals, operating under different rules within different cultures. This presentation of the system represents the view from a medical devices perspective.



## HTA Users

Both commissioners and purchasers need Technology Evaluation. However, HTA has traditionally addressed procurement questions, while commissioning relates to services with complex links into technology needs.

## HTA Suppliers

Need to have the **capacity** and **methodologies** to meet the demand for new device and technology evaluations. There are currently over 10,000 different product types

## Industry HTA

The health technology industry want methods of evaluation that HTA users can **trust**; that is **appropriate**; and will not deter innovation or cause undue delay.